The Determination of the Minimum Safe Level of Interleukin 10IL—10 in (7)
[12] Schreiber S， Fedorak RN， Nielsen OH， Wild G， Williams CN， Nikolaus S， Jacyna M， Lashner BA， Gangl A， Rutgeerts P， Isaacs K， van Deventer SJ， Koningsberger JC， Cohard M， LeBeaut A， Hanauer SB (December 2000). "Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group". Gastroenterology. 119 (6)：1461–72. doi：10.1053/gast.2000.20196.PMID 11113067.
[13] Infante JR， Naing A， Papadopoulos KP， Autio KA， Ott PA， Wong DJ， Falchook GS， Patel MR， Pant S (2015-05-20). "A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors". ASCO Meeting Abstracts. 33 (15
[14] Redford， P. S.， P. J. Murray， and A. O’Garra.( 2011). "The role of IL-10 in immuneregulation during M. tuberculosis infection". Mucosal Immunology4： 261–270.
[15] Verbon， A.， N. Juffermans， S. J. Van Deventer， P. Speelman， H. Van Deutekom，and T. Van Der Poll. 1999. Serum concentrations of cytokines in patients withactive tuberculosis (TB) and after treatment. Clin. Exp. Immunol. 115： 110–113.
[16] Bonecini-Almeida， M. G.， J. L. Ho， N. Boe′chat， R. C. Huard， S. Chitale， H. Doo，J. Geng， L. Rego， L. C. Lazzarini， A. L. Kritski， et al. 2004. Down-modulation oflung immune responses by interleukin-10 and transforming growth factor b(TGF-b) and analysis of TGF-b receptors I and II in active tuberculosis. Infect.Immun. 72： 2628–2634.
, 百拇医药
[17] Almeida， A. S.， P. M. Lago， N. Boechat， R. C. Huard， L. C. Lazzarini，A. R. Santos， M. Nociari， H. Zhu， B. M. Perez-Sweeney， H. Bang， et al. 2009. "Tuberculosis is associated with a down-modulatory lung immune response thatimpairs Th1-type immunity." Journal Immunology. 183： 718–731.
[18] Awomoyi， A. A.， A. Marchant， J. M. Howson， K. P. McAdam， J. M. Blackwell，and M. J. Newport. 2002. Interleukin-10， polymorphism in SLC11A1 (formerlyNRAMP1)， and susceptibility to tuberculosis. J. Infect. Dis. 186： 1808–1814.
, http://www.100md.com
[19] Zhang， M.， J. Gong， D. V. Iyer， B. E. Jones， R. L. Modlin， and P. F. Barnes. 1994.T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J. Clin. Invest. 94： 2435–2442.
[20] O’Leary， S.， M. P. O’Sullivan， and J. Keane. 2011. IL-10 blocks phagosomematuration in mycobacterium tuberculosis-infected human macrophages. Am. J.Respir. Cell Mol. Biol. 45： 172–180.
[21] Jonathan M. Pitt， Evangelos Stavropoulos， Paul S. Redford， Amy M. Beebe， Gregory J. Bancroft， Douglas B. Young and Anne O’Garra "Blockade of IL-10 Signaling during Bacillus Calmette-Guérin Vaccination Enhances and Sustains Th1， Th17， and Innate Lymphoid IFN-γ and IL-17 Responses and Increases Protection toMycobacterium tuberculosis Infection"(October 15， 2012)Journal of Immunology， 189 (8) 4079-4087；DOI：https：//doi.org/10.4049/Journal immunology1201061, 百拇医药(ChangTai. Li)
[13] Infante JR， Naing A， Papadopoulos KP， Autio KA， Ott PA， Wong DJ， Falchook GS， Patel MR， Pant S (2015-05-20). "A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors". ASCO Meeting Abstracts. 33 (15
[14] Redford， P. S.， P. J. Murray， and A. O’Garra.( 2011). "The role of IL-10 in immuneregulation during M. tuberculosis infection". Mucosal Immunology4： 261–270.
[15] Verbon， A.， N. Juffermans， S. J. Van Deventer， P. Speelman， H. Van Deutekom，and T. Van Der Poll. 1999. Serum concentrations of cytokines in patients withactive tuberculosis (TB) and after treatment. Clin. Exp. Immunol. 115： 110–113.
[16] Bonecini-Almeida， M. G.， J. L. Ho， N. Boe′chat， R. C. Huard， S. Chitale， H. Doo，J. Geng， L. Rego， L. C. Lazzarini， A. L. Kritski， et al. 2004. Down-modulation oflung immune responses by interleukin-10 and transforming growth factor b(TGF-b) and analysis of TGF-b receptors I and II in active tuberculosis. Infect.Immun. 72： 2628–2634.
, 百拇医药
[17] Almeida， A. S.， P. M. Lago， N. Boechat， R. C. Huard， L. C. Lazzarini，A. R. Santos， M. Nociari， H. Zhu， B. M. Perez-Sweeney， H. Bang， et al. 2009. "Tuberculosis is associated with a down-modulatory lung immune response thatimpairs Th1-type immunity." Journal Immunology. 183： 718–731.
[18] Awomoyi， A. A.， A. Marchant， J. M. Howson， K. P. McAdam， J. M. Blackwell，and M. J. Newport. 2002. Interleukin-10， polymorphism in SLC11A1 (formerlyNRAMP1)， and susceptibility to tuberculosis. J. Infect. Dis. 186： 1808–1814.
, http://www.100md.com
[19] Zhang， M.， J. Gong， D. V. Iyer， B. E. Jones， R. L. Modlin， and P. F. Barnes. 1994.T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J. Clin. Invest. 94： 2435–2442.
[20] O’Leary， S.， M. P. O’Sullivan， and J. Keane. 2011. IL-10 blocks phagosomematuration in mycobacterium tuberculosis-infected human macrophages. Am. J.Respir. Cell Mol. Biol. 45： 172–180.
[21] Jonathan M. Pitt， Evangelos Stavropoulos， Paul S. Redford， Amy M. Beebe， Gregory J. Bancroft， Douglas B. Young and Anne O’Garra "Blockade of IL-10 Signaling during Bacillus Calmette-Guérin Vaccination Enhances and Sustains Th1， Th17， and Innate Lymphoid IFN-γ and IL-17 Responses and Increases Protection toMycobacterium tuberculosis Infection"(October 15， 2012)Journal of Immunology， 189 (8) 4079-4087；DOI：https：//doi.org/10.4049/Journal immunology1201061, 百拇医药(ChangTai. Li)